Lucid Diagnostics Inc.

Canaccord Genuity acts as Joint Bookrunning Manager for $70.0 million initial public offering of common stock by Lucid Diagnostics Inc.

Canaccord Genuity is pleased to announce that on October 18, 2021, it completed an initial public offering of common stock for Lucid Diagnostics Inc. (NASDAQ: LUCD) (the “Company”). The Company issued a total of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $70.0 million. The Company intends to use the net proceeds from the offering to expand its commercial operations across multiple channels, grow its sales infrastructure across the US, complete ongoing clinical trials, and expand its telemedicine program alongside existing test centers, deploying direct-to-consumer marketing to drive self-referrals to the program. The Company may also use a portion of the net proceeds to expand manufacturing and laboratory capacity to accommodate increased commercial and clinical trial activities.

Canaccord Genuity acted as Joint Bookrunning Manager for the offering.

Lucid Diagnostics Inc. is a medical technology and diagnostics company that develops solutions for the treatment of patients with long-standing gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (will lead to ~16,000 US deaths in 2021). The Company’s vision is to prevent esophageal adenocarcinoma deaths through the early detection of esophageal precancer and cancer in at-risk GERD patients, establishing its solutions as the standard of care.

We would welcome the chance to work with you in the future. Please feel free to contact any of our team members if we can be of assistance.